Kerendia (finerenone) is the first drug in its class to show a benefit ... Bayer is running an open-label study – CONFIRMATION-HF – testing Kerendia with Jardiance in patients hospitalised ...

On the heels of approvals in the US, Europe and Japan, Bayer's Kerendia for ... Analysts think the drug has could reach annual sales of $2 billion or more if its label is extended to reflect ...

GlobalData’s analysis starts in the year the FDA expanded the Jardiance label. Back then ... s stem cell therapy Revascor and Bayer’s Kerendia as other promising prospects.

These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...